Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

The Lancet · 1998 · 20.1K citations

Medicine, Endocrinology, Pharmacotherapy +13

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

The Lancet · 1998 · 8.3K citations

Medicine, Endocrinology, Pharmacotherapy +17

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel et al. · New England Journal of Medicine · 2008 · 7.8K citations · Full text

Medicine, Endocrinology, Internal Medicine +13

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

Steven E. Kahn, Steven M. Haffner, Mark Heise et al. · New England Journal of Medicine · 2006 · 2.9K citations

Medicine, Endocrinology, Pharmacotherapy +13